Partnership between Bora Pharmaceuticals and TaiRx, Inc. for anticancer drug manufacturing
A partnership between Bora Pharmaceuticals and TaiRx, Inc. is expected to support the manufacturing of breakthrough anticancer drug CVM-1118, with two phase II clinical trials to commence.
Bora Pharmaceuticals Laboratories Inc. in Zhunan, Taiwan, has partnered with new drug development company TaiRx, Inc. for the production and manufacture of the novel anticancer drug CVM-1118.
The small molecule therapeutic is a novel chemical entity developed by TaiRx Inc. as an anticancer agent for numerous human cancer cell lines. The drug boasts a strong anticancer activity profile, along with a high safety margin and multiple mechanisms of action when targeting cancer-specific factors. CVM-1118 utilises a novel mechanism involving the inhibition of vasculogenic mimicry, a structure associated with metastasis and drug-induced resistance in malignant tumours. In a phase I study by the US FDA, the safety of oral administration of CVM-1118 was demonstrated and obtained approval for the commencement of two phase II clinical trials by the US FDA and Taiwan FDA.
Bora Pharmaceuticals, an international CDMO specialising in complex oral solid dosages and other modes of administration, will provide sites for the manufacturing of the phase II clinical trial batches, with submission to the NDA for approval. CEO of Bora Pharmaceuticals Bobby Sheng commented on the partnership: “We are extremely excited about this new partnership with TaiRx. As a trusted global pharmaceutical partner, we look forward [to] providing many of our technical and quality resources to TaiRx and supporting them on this important project.”
Du-Shieng Chien, President and CEO of TaiRx Inc. Further added: “As we enter the second stage of clinical trials, we hope our success continues and we hope to gain approval from the NDA for CVM-1118 in the near future.”
The partnership comes on the heels of Bora Pharmaceuticals acquisition of a USD $100 million Biologics site in Taiwan as part of a 5-year plan to grow and develop. Such investment is aimed at increasing Bora Pharmaceuticals’ capabilities in biologics manufacturing and to provide customer support with high-quality manufacturing facilities for innovative pharmaceutical products.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance